New Intranasal Vaccine Targets Drug-Resistant Tuberculosis

Researchers from Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health have developed a novel therapeutic DNA vaccine aimed at combating tuberculosis (TB), particularly targeting drug-tolerant bacterial "persisters." Published in the *Journal of Clinical Investigation*, the study highlights the vaccine's potential to enhance treatment outcomes for TB, which remains a significant global health challenge, affecting approximately 2 billion people worldwide.

SciTechDaily

The vaccine combines two genes, rel Mtb and Mip3?, and is administered intranasally. This method is designed to stimulate the immune system directly in the respiratory tract, where TB infections occur. Styliani Karanika, M.D., the study's lead author, explains that the fusion of these genes produces a signal that attracts immature dendritic cells. These cells are crucial for presenting TB proteins to T cells, which coordinate the immune response against the bacteria. The intranasal delivery aims to generate long-lasting localized T-cell immunity in the lungs, alongside systemic immune responses.

SciTechDaily

In mouse studies, the vaccine demonstrated an ability to accelerate the clearance of TB bacteria, reduce lung inflammation, and prevent relapse after treatment. Additionally, it enhanced the efficacy of existing TB drug combinations, including bedaquiline, pretomanid, and linezolid, suggesting its potential utility in treating drug-resistant TB cases. Rhesus macaque studies further indicated that the vaccine elicited significant TB-specific immune responses, lasting at least six months, although these studies did not assess protection against actual TB infection.

SciTechDaily

The findings support a shift towards immunotherapy strategies that target TB persisters, rather than relying solely on antibiotics to eliminate actively growing bacteria. The researchers emphasize that DNA vaccines are relatively stable and can be produced efficiently, which could facilitate their application in human clinical trials if proven effective.

SciTechDaily

Karanika noted, “Administered together with first-line TB drug therapy, our intranasal DNA fusion vaccine helped infected mice clear the disease bacteria faster.” She also highlighted the importance of the vaccine in enhancing the effectiveness of existing treatments against drug-resistant TB.

SciTechDaily

While the study presents promising results, it is important to note that further research is necessary before advancing to human clinical trials. Critics may point out the need for comprehensive testing to ensure the vaccine's safety and efficacy in humans, as the current studies have only measured immune responses without evaluating actual protection against TB infection.

SciTechDaily

There are currently no conflicting reports regarding the vaccine's efficacy in preclinical models; however, the transition to human trials remains a significant step that has yet to be undertaken. The study's findings are encouraging, but the lack of direct testing against TB infection in humans leaves a gap in understanding the vaccine's full potential.

SciTechDaily

The research team plans to conduct additional preclinical studies to further evaluate the vaccine's protective effects before initiating human clinical trials. The ongoing exploration of immunotherapy approaches could reshape the landscape of TB treatment, particularly in addressing drug-resistant strains.

SciTechDaily